angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-29 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
There are also the testimonies of Raymond Queneau (1903–1976), born in Le Havre, the city served as a framework for his novel Un rude hiver (A harsh winter) (1939). The plot of Une maison soufflée aux vents (A house blown to the winds) by Émile Danoën, winner of the Popular Novel Prize in 1951, and its sequel Idylle dans un quartier muré (Idyll in a walled neighbourhood) were located in Le Havre during the Second World War. Under the name Port de Brume Le Havre is the setting for three other novels by this author: Cerfs-volants (Kites), L'Aventure de Noël (The Adventure at Christmas), and La Queue à la pègre (Queue to the underworld). Michel Leiris wrote De la littérature considérée comme une tauromachie (Of literature considered like a bullfight) in December 1945. Diana Gabaldon set the second novel in her Outlander series, Dragonfly in Amber (1992), partly in Le Havre. Two mystery novels take place in Le Havre: Le Bilan Maletras (The Maletras Balance) by Georges Simenon and Le Crime de Rouletabille (Crime at the Roulette table) by Gaston Leroux. In Rouge Brésil (Red Brazil), winner of the Goncourt Prize in 2001, Jean-Christophe Rufin describes Le Havre in the 16th century as the port of departure of French expeditions to the New World: the hero Villegagnon leaves of the port to conquer new lands for the French crown which become Brazil. Martine–Marie Muller tells the saga of a clan of Stevedores from Le Havre in the 1950s to the 1970s in Quai des Amériques (Quay of the Americas).
=== Post-translational modifications and cofactors === Phosphorylation of the N-terminus not only prevents MDM2 binding but also facilitates the recruitment of cofactors. Pin1 enhances conformational changes in p53, while p300 and PCAF acetylate the C-terminus, exposing the DNA-binding domain and enhancing transcriptional activation. Conversely, deacetylases such as Sirt1 and Sirt7 remove these modifications, suppressing apoptosis and promoting cell survival. Some oncogenes can also activate p53 indirectly by inhibiting MDM2.
=== Other data === Calciseptine has an effect on the K+-induced contractions and L-type Ca2+ channel activity, the IC50 values were determined and gave values of 230 and 430 nM respectively. Calciseptine also has an effect on the cardiac function. The IC50 value found for this tissue was 15 nM. These values were determined in rats and mice.
=== Primary structure === Chymopapain's zymogen is made up of a total of 352 residues, and it has a weight of approximately 23.78kDa. Three different regions can be distinguished inside the precursor's chain.
Sources: en.wikipedia.org
Your structure will completely collapse across the entire continent." Guyana: President Irfaan Ali stated that Guyana has activated its security plan, declaring that "the Guyana Defence Force and the security forces are monitoring the situation and Guyanese should be reassured that the government is working to ensure the safety and security of our citizens." Paraguay: The Ministry of Foreign Affairs issued a statement reaffirming the country's "historic commitment to the peaceful resolution of international disputes". It also referred to Maduro as the "leader" of the Cartel of the Suns (declared a terrorist organization by the Paraguayan government) and stated that his continued hold on power posed a threat to the region. President Santiago Peña later approved the strikes, stating that "it can only bring good news". Peru: President José Jerí welcomed the intervention, stating that "Venezuela is beginning a new era of democracy and freedom." Similarly, he mentioned that "many families will be able to reunite in their country, so we will facilitate their immediate return regardless of their immigration status." Uruguay: The Ministry of Foreign Relations condemned the US intervention in Venezuela, calling on the US to adhere to the UN Charter and respect Venezuela's sovereignty.
Congenital hypofibrinogenemia is a rare inherited disorder in which blood may not clot normally due to reduced levels of fibrinogen (plasma fibrinogen typically <150 but >50 mg/dl). The disorder reflects a disruptive mutation in only one of the two parental FGA, FGB, or FBG genes and has a low degree of genetic penetrance, i.e. only some family members with the defective gene ever exhibit symptoms. Symptoms of the disorder, which more often occurs in individuals with lower plasma fibrinogen levels, include episodic bleeding and thrombosis that typically begin in late childhood or adulthood.
NAD+-β-hydroxybutyrate dehydrogenase hydroxybutyrate oxidoreductase β-hydroxybutyrate dehydrogenase D-β-hydroxybutyrate dehydrogenase D-3-hydroxybutyrate dehydrogenase D-(−)-3-hydroxybutyrate dehydrogenase β-hydroxybutyric acid dehydrogenase 3-D-hydroxybutyrate dehydrogenase β-hydroxybutyric dehydrogenase
Sources: en.wikipedia.org
(G71.3) Mitochondrial myopathies, which are due to defects in mitochondria, which provide a critical source of energy for muscle (G72.3) Familial periodic paralysis (G72.4) Inflammatory myopathies, which are caused by problems with the immune system attacking components of the muscle, leading to signs of inflammation in the muscle (G73.6) Metabolic myopathies, which result from defects in biochemical metabolism that primarily affect muscle (G73.6/E74.0) Glycogen storage diseases, which may affect muscle (G73.6/E75) Lipid storage disorder (G72.89) Other myopathies Brody myopathy Congenital myopathy with abnormal subcellular organelles Fingerprint body myopathy Inclusion body myopathy 2 Megaconial myopathy Myofibrillar myopathy Rimmed vacuolar myopathy
On 18 January 2024, Natalia Kanem, the executive director of the UN Population Fund, spoke at the World Economic Forum at Davos, stating the situation was the "worst nightmare" the UNPF representative had ever witnessed, as there were 180 women giving birth daily, sometimes on the streets of Gaza, as the territory's health system collapsed. On 17 January, Care International reported a 300 percent increase in the rate of miscarriage in Gaza since the start of Israel's bombing. UNICEF reported on 19 January that 20,000 babies had been born in the Gaza Strip since 7 October. UNICEF described each birth as a baby being "delivered into hell", and stated "humanity cannot allow this warped version of normal to persist any longer." The UN Women's agency reported that since the start of the conflict, two mothers in Gaza had been killed every hour, every day. WHO reported an increase in stress-induced stillbirths. Doctors Without Borders stated that women were giving birth in plastic tents, and that those undergoing C-sections were being released within hours. It also reported that women were being turned away from hospitals due to overcrowding, with some forced to birth in public restrooms. Doctors at Kamal Adwan Hospital performed an emergency c-section on a deceased pregnant woman in February 2024, after which they performed a fetal cardiac resuscitation; however, the baby did not survive.
For many years, arsenic trioxide was administered to patients with various cancers, showing the best results in the treatment of acute promyelocytic leukemia. More than half of the patients from the first trial in Harbin survived for five years, prompting further research across other centers in China, and eventually at the Sloan-Kettering Memorial Institute in New York. The results of clinical trials were favorable enough that in 2000, the drug received FDA approval.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.